MURAL - Maynooth University Research Archive Library

    Enhanced pyrazolopyrimidinones cytotoxicity against glioblastoma cells activated by ROS-Generating cold atmospheric plasma

    He, Zhonglei and Charleton, Clara and Devine, Robert W. and Kelada, Mark and Walsh, John M.D. and Conway, Gillian E. and Gunes, Sebnem and Mondala, Julie Rose Mae and Tian, Furong and Tiwari, Brijesh and Kinsella, Gemma K. and Malone, Renee and O'Shea, Denis and Devereux, Michael and Wang, Wenxin and Cullen, Patrick J. and Stephens, John C. and Curtin, James F. (2021) Enhanced pyrazolopyrimidinones cytotoxicity against glioblastoma cells activated by ROS-Generating cold atmospheric plasma. European Journal of Medicinal Chemistry, 224. p. 113736. ISSN 0223-5234

    Download (2MB) | Preview

    Share your research

    Twitter Facebook LinkedIn GooglePlus Email more...

    Add this article to your Mendeley library


    Pyrazolopyrimidinones are fused nitrogen-containing heterocyclic systems, which act as a core scaffold in many pharmaceutically relevant compounds. Pyrazolopyrimidinones have been demonstrated to be efficient in treating several diseases, including cystic fibrosis, obesity, viral infection and cancer. In this study using glioblastoma U-251MG cell line, we tested the cytotoxic effects of 15 pyrazolopyrimidinones, synthesised via a two-step process, in combination with cold atmospheric plasma (CAP). CAP is an adjustable source of reactive oxygen and nitrogen species as well as other unique chemical and physical effects which has been successfully tested as an innovative cancer therapy in clinical trials. Significantly variable cytotoxicity was observed with IC50 values ranging from around 11 μM to negligible toxicity among tested compounds. Interestingly, two pyrazolopyrimidinones were identified that act in a prodrug fashion and display around 5–15 times enhanced reactive-species dependent cytotoxicity when combined with cold atmospheric plasma. Activation was evident for direct CAP treatment on U-251MG cells loaded with the pyrazolopyrimidinone and indirect CAP treatment of the pyrazolopyrimidinone in media before adding to cells. Our results demonstrated the potential of CAP combined with pyrazolopyrimidinones as a programmable cytotoxic therapy and provide screened scaffolds that can be used for further development of pyrazolopyrimidinone prodrug derivatives.

    Item Type: Article
    Additional Information: Cite as: Zhonglei He, Clara Charleton, Robert W. Devine, Mark Kelada, John M.D. Walsh, Gillian E. Conway, Sebnem Gunes, Julie Rose Mae Mondala, Furong Tian, Brijesh Tiwari, Gemma K. Kinsella, Renee Malone, Denis O'Shea, Michael Devereux, Wenxin Wang, Patrick J. Cullen, John C. Stephens, James F. Curtin, Enhanced pyrazolopyrimidinones cytotoxicity against glioblastoma cells activated by ROS-Generating cold atmospheric plasma, European Journal of Medicinal Chemistry, Volume 224, 2021, 113736, ISSN 0223-5234,
    Keywords: Cold atmospheric plasma;Pyrazolopyrimidinone;Pro-drug;ROS;Glioblastoma;Programmable cytotoxicity
    Academic Unit: Faculty of Science and Engineering > Chemistry
    Faculty of Science and Engineering > Research Institutes > Human Health Institute
    Item ID: 17459
    Identification Number:
    Depositing User: Dr John Stephens
    Date Deposited: 24 Aug 2023 08:44
    Journal or Publication Title: European Journal of Medicinal Chemistry
    Publisher: Elsevier
    Refereed: Yes
    Use Licence: This item is available under a Creative Commons Attribution Non Commercial Share Alike Licence (CC BY-NC-SA). Details of this licence are available here

    Repository Staff Only(login required)

    View Item Item control page


    Downloads per month over past year

    Origin of downloads